Roche seeks to broaden arthritis drug use in EU, US - Reuters

Roche seeks to broaden arthritis drug use in EU, US Reuters The drug is mainly targeted at rheumatoid arthritis, but a late-stage study published in June showed it improved the signs and symptoms of sJIA. ... ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations ...PipelineReview.com (press release) Roche files to get sJIA on RoActemra labelPharma Times Roche seeks approval for arthritis drugIrish Times all 9 news articles »

Looking Into Pharmas - Seeking Alpha

Looking Into Pharmas Seeking Alpha This segment's products also comprise Celebrex for osteoarthritis and rheumatoid arthritis and acute pain; Zyvox for Gram-positive pathogens; ... and more »

Myositis Diagnosis, Treatment Remains Complex - Skin and Allergy News Digital Network

Myositis Diagnosis, Treatment Remains Complex Skin and Allergy News Digital Network Dermatomyositis is the most common form of myositis in childhood, and there may be other symptoms as well, including a heliotrope rash over the eyelids and ...

Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohn's ... - PR Newswire (press release)

Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohn's ... PR Newswire (press release) It is also approved for the treatment of adults with moderately to severely active rheumatoid arthritis. Certolizumab pegol was approved in Switzerland for ... and more »